Cargo and Functional Profile of Saliva-Derived Exosomes Reveal Biomarkers Specific for Head and Neck Cancer.
exosomes
head and neck squamous cell carcinoma (HNSCC)
liquid biopsy
miRNA
saliva
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
03
2022
accepted:
20
06
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Exosomes contribute to immunosuppression in head and neck squamous cell carcinoma (HNSCC), a tumor entity which lacks specific tumor biomarkers. Plasma-derived exosomes from HNSCC patients correlate with clinical parameters and have potential as liquid biopsy. Here, we investigate the cargo and functional profile of saliva-derived exosomes from HNSCC patients and their potential as non-invasive biomarkers for disease detection and immunomodulation. Exosomes were isolated from saliva of HNSCC patients ( Saliva-derived, CD63-captured exosomes from HNSCC patients carried high amounts of CD44v3, PDL1 and CD39. Compared to plasma, saliva was rich in tumor-derived, CD44v3 Saliva-derived exosomes from HNSCC patients were enriched in tumor-derived exosomes whose cargo and functional profile reflected an immunosuppressive TME. Surface values of CD44v3, PDL1 and CD39 on CD63-captured exosomes, adenosine production and the miRNA cargo of saliva-derived exosomes emerged as discriminators of disease and emphasized their potential as liquid biomarkers specific for HNSCC.
Sections du résumé
Background
UNASSIGNED
Exosomes contribute to immunosuppression in head and neck squamous cell carcinoma (HNSCC), a tumor entity which lacks specific tumor biomarkers. Plasma-derived exosomes from HNSCC patients correlate with clinical parameters and have potential as liquid biopsy. Here, we investigate the cargo and functional profile of saliva-derived exosomes from HNSCC patients and their potential as non-invasive biomarkers for disease detection and immunomodulation.
Methods
UNASSIGNED
Exosomes were isolated from saliva of HNSCC patients (
Results
UNASSIGNED
Saliva-derived, CD63-captured exosomes from HNSCC patients carried high amounts of CD44v3, PDL1 and CD39. Compared to plasma, saliva was rich in tumor-derived, CD44v3
Conclusions
UNASSIGNED
Saliva-derived exosomes from HNSCC patients were enriched in tumor-derived exosomes whose cargo and functional profile reflected an immunosuppressive TME. Surface values of CD44v3, PDL1 and CD39 on CD63-captured exosomes, adenosine production and the miRNA cargo of saliva-derived exosomes emerged as discriminators of disease and emphasized their potential as liquid biomarkers specific for HNSCC.
Identifiants
pubmed: 35899209
doi: 10.3389/fmed.2022.904295
pmc: PMC9309685
doi:
Types de publication
Journal Article
Langues
eng
Pagination
904295Informations de copyright
Copyright © 2022 Hofmann, Medyany, Ezić, Lotfi, Niesler, Röth, Engelhardt, Laban, Schuler, Hoffmann, Brunner, Jackson and Theodoraki.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Adv Exp Med Biol. 2020;1258:189-197
pubmed: 32767243
Oncotarget. 2016 Feb 16;7(7):8223-39
pubmed: 26882562
Tumour Biol. 2014 Mar;35(3):2053-62
pubmed: 24122205
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708274
J Oncol. 2021 Apr 16;2021:5547911
pubmed: 33953745
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Front Genet. 2019 Mar 14;10:202
pubmed: 30923536
Cell Mol Neurobiol. 2016 Apr;36(3):301-12
pubmed: 27053351
Sci Rep. 2016 Apr 19;6:24669
pubmed: 27091080
J Histochem Cytochem. 2015 Mar;63(3):181-9
pubmed: 25473095
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
PLoS One. 2012;7(3):e33037
pubmed: 22448232
PLoS One. 2012;7(3):e30679
pubmed: 22427800
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Oncol Rep. 2012 Aug;28(2):465-72
pubmed: 22641236
Cells. 2019 Dec 17;8(12):
pubmed: 31861112
Biomed Pharmacother. 2020 Jan;121:109553
pubmed: 31704611
Int J Oncol. 2016 Jan;48(1):99-109
pubmed: 26647656
J Oral Rehabil. 2018 Sep;45(9):730-746
pubmed: 29878444
BMC Cancer. 2011 Feb 07;11:57
pubmed: 21299870
Cancer Lett. 2014 Jan 1;342(1):121-9
pubmed: 24001611
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
Oxid Med Cell Longev. 2018 Nov 6;2018:4692081
pubmed: 30524655
J Cancer Res Clin Oncol. 2016 Jan;142(1):101-10
pubmed: 26115960
Enzymes. 2017;42:125-151
pubmed: 29054268
Anal Chim Acta. 2017 Aug 22;982:84-95
pubmed: 28734369
Curr Neuropharmacol. 2017;15(1):157-165
pubmed: 27568544
Life Sci Alliance. 2020 May 7;3(6):
pubmed: 32381551
Oncotarget. 2017 Jul 27;8(47):82459-82474
pubmed: 29137278
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2019 Feb;120(3):317-330
pubmed: 30555157
Clin Cancer Res. 2018 Feb 15;24(4):896-905
pubmed: 29233903
Oral Dis. 2010 Jan;16(1):34-8
pubmed: 19627513
J Biol Chem. 2013 Sep 13;288(37):26888-97
pubmed: 23880764
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
J Immunol. 2011 Jul 15;187(2):676-83
pubmed: 21677139
Clin Exp Immunol. 2017 Sep;189(3):259-267
pubmed: 28369805
Int J Biol Sci. 2021 Jan 1;17(1):163-177
pubmed: 33390841
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Sci Rep. 2015 Nov 05;5:16305
pubmed: 26538482
J Exp Clin Cancer Res. 2017 Oct 5;36(1):138
pubmed: 28982387
J Cancer. 2020 Jul 9;11(18):5329-5344
pubmed: 32742479
Science. 1997 Dec 5;278(5344):1812-5
pubmed: 9388187
Clin Exp Immunol. 2014 Aug;177(2):531-43
pubmed: 24749746
Oncoimmunology. 2017 Jul 19;6(8):e1261243
pubmed: 28919985
Cell Biosci. 2011 Dec 28;1:41
pubmed: 22204491
Int J Cancer. 2010 Dec 15;127(12):2804-14
pubmed: 21351259
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32
pubmed: 11283501
Laryngoscope Investig Otolaryngol. 2017 May 20;2(4):194-198
pubmed: 28894840
Anticancer Res. 2015 Jul;35(7):3953-60
pubmed: 26124342
Int J Mol Sci. 2020 Jun 06;21(11):
pubmed: 32517240
Langmuir. 2011 Dec 6;27(23):14394-400
pubmed: 22017459
Int J Mol Sci. 2020 May 26;21(11):
pubmed: 32466374
Clin Exp Immunol. 2018 Jun;192(3):271-283
pubmed: 29431869
FASEB J. 2017 Mar;31(3):998-1010
pubmed: 27895106
Biochem Biophys Res Commun. 2012 Feb 10;418(2):378-83
pubmed: 22266319
Int J Mol Sci. 2015 Sep 07;16(9):21294-309
pubmed: 26370963
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Front Biosci (Landmark Ed). 2012 Jan 01;17(4):1281-93
pubmed: 22201803
Br J Cancer. 2021 Dec;125(12):1677-1686
pubmed: 34642463
Clin Exp Immunol. 2018 Oct;194(1):67-78
pubmed: 30229863
BMC Cancer. 2018 Apr 18;18(1):439
pubmed: 29669525
Cytometry A. 2021 Apr;99(4):372-381
pubmed: 33448645
Drug Alcohol Depend. 2019 Nov 1;204:107510
pubmed: 31494441
Oncoimmunology. 2020 Apr 7;9(1):1747732
pubmed: 32313730
Oncol Rep. 2011 Jun;25(6):1581-7
pubmed: 21479366
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906